Physician profile
Adnan Cemer
NPI 1053577734
$13,342.17
in general payments reported to CMS, 2019-2025
36 companies · $16.19 in 2025
The $16.19 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,900 · 2020: $1,194 · 2021: $2,695 · 2022: $3,778 · 2023: $2,565 · 2024: $195 · 2025: $16.19.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,776.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,775.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,883.35 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,418.67 | 2021-2023 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,324.97 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $1,048.54 | 2019-2023 | Trelegy Ellipta, Shingrix, Bexsero |
| Lilly USA, LLC | $998.47 | 2019-2023 | Mounjaro, Jardiance, Emgality |
| Merck Sharp & Dohme LLC | $638.71 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Astellas Pharma US INC | $610.84 | 2019-2023 | Myrbetriq, Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $546.58 | 2019-2023 | Synjardy, Jardiance |
| Pfizer INC. | $544.02 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $454.92 | 2021-2023 | |
| Abbott Laboratories | $421.11 | 2021-2023 | Freestyle Libre 3 |
| Allergan, INC. | $386.71 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $356.18 | 2019-2023 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $287.65 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $272.84 | 2021 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adnan Cemer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.